Samina Syed, MD
Endocrinology, Diabetes & Metabolism · Madison, WINPI 1851565212
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 56 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 16 manufacturers, the largest accounting for just 17.3% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $390, 9.7 times the $40 reported in 2019.
Across 56 payments — averaging $18.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$175
- Abbott$174
- Novo Nordisk$166
- Amgen$118
- Recordati_rare_diseases_inc.$61
- Insulet Corporation$53
- plus $263 from 10 others
What the payments were for
- Food & beverage$1,010100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 10 | $175 |
| Abbott | 10 | $174 |
| Novo Nordisk | 9 | $166 |
| Amgen(2 entities) | 8 | $118 |
| Recordati_rare_diseases_inc. | 3 | $61 |
| Insulet Corporation | 2 | $53 |
| Medtronic | 2 | $43 |
| Amphastar Pharmaceuticals, Inc. | 2 | $38 |
| Neurocrine Biosciences, Inc. | 1 | $35 |
| Pfizer | 2 | $35 |
| AstraZeneca(2 entities) | 2 | $31 |
| Sequel Med Tech, LLC | 1 | $20 |
| Sanofi-aventis U.S. LLC | 1 | $18 |
| Amneal Pharmaceuticals LLC | 1 | $16 |
| Ardelyx, Inc. | 1 | $15 |
| Amarin Pharma, Inc. | 1 | $12 |
How this compares
$1,010 in reported general payments places this provider in the 70th percentile of 127 endocrinology, diabetes & metabolism providers in Wisconsin.
See all endocrinology, diabetes & metabolism providers in Wisconsin →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 150 | $211,035 |
| OzempicSemaglutide | 80 | $154,293 |
| JardianceEmpagliflozin | 92 | $125,077 |
| JanuviaSitagliptin Phosphate | 71 | $97,648 |
| TrulicityDulaglutide | 29 | $64,450 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 45 | $40,802 |
| Novolog FlexpenInsulin Aspart | 92 | $28,301 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 151 | $27,914 |
| FarxigaDapagliflozin Propanediol | 17 | $22,599 |
| SynthroidLevothyroxine Sodium | 175 | $19,033 |
| RybelsusSemaglutide | 12 | $17,817 |
| Humalog Kwikpen U-100Insulin Lispro | 35 | $12,406 |
| Nano 2nd Gen Pen NeedlePen Needle, Diabetic | 53 | $7,277 |
| LevoxylLevothyroxine Sodium | 200 | $6,559 |
| Levothyroxine Sodium | 401 | $5,197 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $166 | $172,10992 claims |
| AstraZenecaFarxiga | $31 | $22,59917 claims |
| AbbVieSynthroid | $175 | $19,033175 claims |
| PfizerLevoxyl | $35 | $6,559200 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $16 | $5,197401 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 127 endocrinology, diabetes & metabolism providers in Wisconsin.
Other endocrinology, diabetes & metabolism in Madison
- Neil BinkleyMadison$76K
- Gihan DawoodMadison$22K
- Ty CarrollMadison$14K
- Dawn DavisMadison$9K
- Samantha PabichMadison$5K
- Kim Keppler-NoreuilMadison$4K
- Sorin HerscoviciMadison$2K
- Aron AdkinsEau Claire$349K
- Steven RabinoweRacine$344K
- Daniel Shortla Crosse$328K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.